SIX-MONTH STANDING ORDER – QUIDEL ORTHO REAGENTS

This is a notice of intent, NOT a request for a quotation. A solicitation document will NOT be issued, and quotations will NOT be requested.

The National Institutes of Health on behalf of the Department of Transfusion Medicine  intends to award a firm-fixed-price purchase order on a sole source basis to:
QuidelOrtho Sales Company, LLC
9975 Summers Ridge Road
San Diego, CA 92121-2997

Decription of Requirement

Six (6) month standing order for QuidelOrtho reagents.

Period of Performance:
April 1, 2026 – September 30, 2026

Supplies

Anti-IgG gel cards (MTS084024)
MTS A/B/D Mono and Reverse gel cards (MTS080515)
Anti-IgG C3d gel cards (MTS084014)
Surgiscreen (6902316)
Affirmagen (719201)
Resolve Panel A (6902317)
MTS Round Diluent 2 (MTS9230)
Alba Q-Chek controls (Z498)
MTS Round Diluent 2+ (MTS9330)
BSA 7% (6844285)
MTS Buffered Gel card (MTS085014)

Justification

QuidelOrtho reagents are the only reagents compatible with the existing Vision analyzer currently used in the department.
No authorized distributors exist. Alternate products would require validation and delay patient care.

Authority

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Submission

Email capability statements only  to:
shasheshe.goolsby@nih.gov

Deadline:
March 25, 2026 at 09:30 AM EST